uniQure N.V. (QURE)
NASDAQ: QURE · IEX Real-Time Price · USD
7.50
-0.24 (-3.10%)
Jul 22, 2024, 10:16 AM EDT - Market open
uniQure Employees
uniQure had 480 employees as of December 31, 2023. The number of employees decreased by 21 or -4.19% compared to the previous year.
Employees
480
Change (1Y)
-21
Growth (1Y)
-4.19%
Revenue / Employee
$39,590
Profits / Employee
-$618,477
Market Cap
376.50M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Organogenesis Holdings | 862 |
Revance Therapeutics | 597 |
Talkspace | 472 |
Sight Sciences | 214 |
Vanda Pharmaceuticals | 203 |
TScan Therapeutics | 154 |
Lexeo Therapeutics | 58 |
Tourmaline Bio | 44 |
QURE News
- 10 days ago - What Led To A 150% Rise In UniQure Stock In A Week? - Forbes
- 13 days ago - uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease - GlobeNewsWire
- 21 days ago - uniQure Announces Sale of Commercial Manufacturing Facility to Genezen - GlobeNewsWire
- 21 days ago - Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA - PRNewsWire
- 7 weeks ago - uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease - GlobeNewsWire
- 2 months ago - uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 5 months ago - uniQure Announces 2023 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 7 months ago - uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease - GlobeNewsWire